Get started

CLVS

Here 'l'll Let You in on a Little Secret:It's Called Gun and RunThat's what happened. Market makers pump up the share price in the premarket or in the after hours, then short it at artificially inflated prices to everybody in the morning. Think of it like an investment. You buy $2 million worth of stock for, let's say $25.00, then sell $20 million worth of stock for $26; then you cover when the price tanks in the morning. Of course nothing is guaranteed and it could go wrong, but the risk reward is very strong Those figures could be an exaggeration because I've never done it before and nor am I a market maker, but you get the jist. Nobody knows that by the way. Just letting you know. I found that out by pure chance, and maybe by the grace of god.
NASDAQ:AMRN
by InteractiveSwingTrading
1
One possible path for CLVSA few thoughts on CLVS. May not pan out, but this is a bullish scenario. Reasons the bull scenario could play out from a technical standpoint: 1. Move up to $99 was a clear 5 waves. It looks to have recently completed the ABC correction into a perfect golden pocket 61.8 to 65% retracement. 2. Wave C was an ending diagonal. CLVS has broken out of the diagonal to the upside after a throw over to the downside (a common occurrence in diagonals). 3. Wave 1 up of the new trend has already retraced about 50%. If it gets to the $53-54 range soon, that will make a 61.8% retracement of wave 1 up. Aggressive traders might be looking to buy the drop to the $53 range hoping the above scenario is correct. More conservative traders might wait for it to break the high of wave 1 around $63 for confirmation of a new uptrend. I have no position at this time, but will be watching closely and may enter a position in the future. Obviously, the bear scenario (which does not really need much chart elaboration) would be that the current downward movement continues to the lower trendline, possibly testing the low $40's in the near future.
C
by CryptoTA4U
CLVS share discount pricing won't last longBig recovery moves when it hits the bottom trend line last two times, about to do the same a third time. Probably a coincidence, but both of the previous take downs were followed by some good news. It wouldn't be too surprising if someone out there knows something we don't and is trying to shake out weak hands to get cheap shares. Expecting this to be $90+ soon. Rolling NDA submission for Rocilentinib will be completed by July/August and will serve as another positive catalyst. Although CLVS management has said on the record that they are planning to bring their drugs to market on their own, I still believe they are just playing hard to get for now to minimize rampant speculation and liability of forward-looking statements. Current market cap sits around $2.8B with peak sales potential of about $2B/year for Rocilentinib. This doesn't even fully take into account Rucaparib that will likely file its NDA in 1Q16 and will compete with already approved Lynparza by AstraZeneca (AZN) that has $3B/yr sales potential. A buyout offer of at least $6-10B will be difficult to refuse, and even without the offer, the company deserves a valuation of $160+ once Rocilentinib is approved.
CLong
by Elemental